This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E72.4 (urea cycle disorder) | Special Copayment Reduction: V117 (rare disease) |
| B. Synonyms | Gyrate atrophy of choroid and retina, ornithine aminotransferase deficiency (OAT deficiency), hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (HHH syndrome), ornithine carrier deficiency (ORNT1 deficiency), Hyperornithinemia type I/II |
| C. Adult onset | Likelihood of adult presentation: high (gyrate atrophy) — gyrate atrophy often begins in childhood with reduced night vision and is diagnosed in adulthood, and HHH syndrome in its late-onset form may also first present in adulthood with seizures or cognitive decline. |
| 1. History | 1973 first description of gyrate atrophy by Takki → 1977 Valle confirmed OAT enzyme deficiency → 1988 cloning of the OAT gene → 1996 identification of the ORNT1 gene (HHH syndrome). |
| 2. Causes | Gyrate atrophy: OAT gene (10q26) variants → deficiency of mitochondrial ornithine aminotransferase → ornithine accumulation. HHH syndrome: SLC25A15 (ORNT1) gene variants → impaired mitochondrial ornithine transport. |
| 3. Genetics | Both diseases are autosomal recessive. OAT: 10q26, 11 exons. SLC25A15: 13q14, 7 exons. High frequency of gyrate atrophy in Finland due to a founder effect. |
| 4. General epidemiology | Gyrate atrophy: ~200 cases reported worldwide, Finland 1:50,000. HHH syndrome: ~130 or fewer cases reported, clustered in Italy and North Africa. Both diseases are ultra-rare. |
| 5. Pathophysiology | Gyrate atrophy: hyperornithinemia → toxicity to retinal and choroidal cells (reduced creatine synthesis, GABA inhibition). HHH: inability of ornithine to enter mitochondria → urea cycle disorder + cytosolic ornithine accumulation + homocitrullinuria. |
| 6. Symptoms | Gyrate atrophy: childhood night blindness → tunnel vision → blindness. HHH: episodes of hyperammonemia (lethargy, vomiting), seizures, progressive spastic paraplegia. |
| 7. Signs | Gyrate atrophy: characteristic circular/scalloped chorioretinal atrophic lesions in the fundus. HHH: triad of hyperammonemia, homocitrullinuria and hyperornithinemia. Spasticity, hyperreflexia. |
| 8. Screening | Plasma amino acids: marked elevation of ornithine is common to both diseases. Early detection possible through elevated ornithine on newborn MS/MS screening. |
| 9. Diagnosis | Plasma amino acids (ornithine↑), urine amino acids, funduscopy·ERG (gyrate atrophy), molecular genetic testing (OAT/SLC25A15). Enzyme activity (skin fibroblasts, lymphocytes). |
| 10. Treatment | Gyrate atrophy: arginine-restricted diet, trial of vitamin B6 (pyridoxine), creatine supplementation. HHH: low-protein diet, citrulline supplementation, ammonia scavengers in the acute phase. |
| 11. Prognosis | Gyrate atrophy: without treatment, blindness in mid-adulthood. Progression can be slowed by dietary control. HHH: neurological damage accumulates with recurrent episodes of hyperammonemia. Spastic paraplegia may continue to progress. |
| 12. Prevention | Genetic counseling, prenatal diagnosis. Gyrate atrophy: early initiation of an arginine-restricted diet. HHH: avoidance of protein triggers, establishment of an emergency management plan. |
| 13. References | Valle D et al. 1980; Takki K 1974; Martinelli D et al. 2015 and 7 other references. |
Ornithine metabolism disorders broadly include two distinct enzyme or transporter deficiency diseases. The first is gyrate atrophy of the choroid and retina due to ornithine aminotransferase (OAT) deficiency, and the second is hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome due to deficiency of the ornithine-citrulline antiporter (ORNT1) of the inner mitochondrial membrane. The two diseases share the common biochemical feature of elevated plasma ornithine but differ in clinical presentation, genes and pathophysiology.
The history of gyrate atrophy begins with the 1973~74 studies of the Finnish ophthalmologist Karita Takki. Takki systematically described several Finnish families with distinctive fundus findings (circular chorioretinal atrophy) and confirmed that the disease is inherited in an autosomal recessive manner. In 1977, David Valle, Irene Kaiser-Kupfer and colleagues demonstrated markedly reduced OAT enzyme activity in skin fibroblasts from patients with gyrate atrophy, establishing enzyme deficiency as the cause. This discovery was the first to prove a causal relationship between hyperornithinemia and retinal atrophy.
Molecular genetic progress began in 1988 when Garry Mitchell, Valle and colleagues cloned the OAT gene (10q26). Several pathogenic variants were subsequently identified, and it was found that in Finland, owing to a founder effect, a specific variant (c.1223G>A, p.Arg403Gln) accounts for about 75% of all patients. Vitamin B6 (pyridoxine)-responsive variants were identified in some patients, and a trial of pyridoxine became part of treatment.
HHH syndrome became known in 1969 when Shih et al. first reported the triad of hyperornithinemia, hyperammonemia and homocitrullinuria. In 1997, Guida et al. identified the causative gene of HHH syndrome as SLC25A15 (ORNT1), located at 13q14, explaining how deficiency of the mitochondrial ornithine transporter simultaneously causes a urea cycle disorder and ornithine accumulation. Clustering due to founder effects is observed in southern Italy and North Africa.
Gyrate atrophy (OAT deficiency): pathogenic variants in the OAT gene (10q26.13) cause loss of function of ornithine aminotransferase (OAT; EC 2.6.1.13), a vitamin B6-dependent enzyme of the mitochondrial matrix. Normally OAT converts ornithine and α-ketoglutarate into pyrroline-5-carboxylate (P5C) and glutamate; this reaction metabolizes ornithine and contributes to proline and glutamate biosynthesis. In OAT deficiency, ornithine accumulates in plasma and tissues, damaging the retinal pigment epithelium (RPE) and choroid. Because vitamin B6 (pyridoxal phosphate, PLP) is the coenzyme of OAT, some variants show pyridoxine responsiveness, in which high-dose pyridoxine increases residual enzyme activity.
HHH syndrome (ORNT1 deficiency): pathogenic variants in the SLC25A15 gene (13q14.11) cause loss of function of the ornithine-citrulline antiporter (ornithine carrier, ORNT1) of the inner mitochondrial membrane. Normally ORNT1 exchanges cytosolic ornithine into the mitochondrial matrix and mitochondrial citrulline into the cytosol. In ORNT1 deficiency, ornithine cannot enter the mitochondria, so the OTC reaction of the urea cycle (ornithine + carbamoyl phosphate → citrulline) is blocked, resulting in hyperammonemia. At the same time, ornithine accumulates in excess in the cytosol, and excess carbamoyl phosphate combines inefficiently with lysine to produce homocitrulline, which is excreted in the urine.
Both diseases are inherited in an autosomal recessive manner, manifesting in 25% of children when both parents are carriers. Compound heterozygosity for two variants within the same gene causes disease just as homozygosity does. The concentrated distribution of founder variants in particular ethnic groups and regions is an epidemiological feature.
The OAT gene is located on the long arm of chromosome 10 (10q26.13) and consists of 11 exons. The encoded protein is a precursor protein of 439 amino acids, which after mitochondrial import is cleaved into the mature monomer (374 amino acids) and assembled into a hexamer to become active. The PLP binding site (Lys292) is central to enzyme activity, and pyridoxine responsiveness is observed with variants around this site. More than about 100 pathogenic OAT variants have been reported to date, and the Finnish founder variant p.Arg403Gln accounts for most Finnish patients.
The SLC25A15 gene is located on the long arm of chromosome 13 (13q14.11) and, with 7 exons, encodes a mitochondrial carrier protein of 301 amino acids. SLC25A15 is a member of the mitochondrial carrier protein family (MCF, Mitochondrial Carrier Family), has 3 repeat domains (tripartite structure) and functions as a homodimer. In patients from southern Italy, the c.535delΔF, p.Phe188del variant is reported as a founder variant, and various other point mutations and small deletions have been identified worldwide. The correlation between variant type and residual transporter function has not been fully elucidated, but complete loss-of-function variants tend to produce the severe neonatal form.
For both diseases, molecular genetic testing (NGS-based whole-gene analysis or targeted panels) is the standard for confirmation. For carrier and prenatal diagnosis, targeted analysis is performed after the family variant has been identified. Enzyme activity measurement (skin fibroblasts or lymphocytes) is used as a supplement to molecular diagnosis.
Gyrate atrophy is an ultra-rare disease with about 200 cases reported in the literature worldwide. The overall incidence is estimated at about 1:1,500,000 births, but in Finland the prevalence is much higher, at about 1:50,000, owing to a founder effect. Outside Finland, sporadic cases have been reported in various ethnic groups, including in Japan, Italy and the Middle East. There are also rare case reports in Korea, and the number of patients registered in the Korean rare disease database is very small.
HHH syndrome is an ultra-rare disease with about 130 or fewer cases reported in the literature worldwide. The incidence is very low, on the order of 1 in several million births. Relatively high frequencies are reported along the southern Mediterranean coast of Italy, in Quebec (Canada) and in North Africa, related to the presence of founder variants in each region. Cases in East Asia are few, but there are case reports from Japan and Korea.
Because both diseases are autosomal recessive, the risk of affected patients increases in populations with a high frequency of consanguineous marriage. Elevated plasma ornithine on newborn screening using tandem mass spectrometry (MS/MS) can serve as a common marker of both diseases, so early diagnosis is possible in countries with well-established screening systems. However, because gyrate atrophy has no clinical symptoms in the neonatal period, ophthalmological follow-up is needed from an early age even if it is detected on screening.
Pathophysiology of gyrate atrophy: owing to OAT deficiency, ornithine accumulates in various body compartments such as plasma, cerebrospinal fluid and aqueous humor (plasma ornithine 500~2000 µmol/L, normal < 100 µmol/L). The exact mechanism by which excess ornithine is toxic to retinal pigment epithelium (RPE) and choroidal cells has not been fully elucidated, but two main hypotheses have been proposed. First, reduced creatine synthesis due to OAT deficiency: ornithine is also involved in the synthesis of creatine precursors via glycine amidinotransferase (AGAT), and the hypothesis is that excess ornithine inhibits this pathway, causing impaired energy metabolism in the retina and muscle. Indeed, reduced muscle creatine is observed in patients with gyrate atrophy. Second, reduced P5C synthesis: pyrroline-5-carboxylate (P5C), the product of the OAT reaction, is reduced, lowering proline and glutamate synthesis, which affects RPE cell function.
Pathophysiology of HHH syndrome: owing to ORNT1 deficiency, cytosolic ornithine cannot enter the mitochondria, so the second step of the urea cycle (the OTC reaction) is blocked. As a result, carbamoyl phosphate (CP) accumulates in the mitochondria, and with the urea cycle blocked, ammonia accumulates in the blood. Ornithine remaining in excess in the cytosol combines inefficiently with lysine to form homocitrulline, which is excreted in the urine. Homocitrullinuria is the characteristic biochemical marker of HHH syndrome. Hyperammonemia causes brain damage through neurotoxic mechanisms similar to OTC deficiency (excess glutamine accumulation in astrocytes, cerebral edema). The mechanism by which spastic paraplegia develops over the long-term course due to white matter damage of the spinal cord tracts is understood as the combined result of chronic hyperammonemia and demyelination of the pyramidal tracts.
Symptoms of gyrate atrophy: clinical symptoms are confined almost entirely to the ocular system. The first symptom to appear is night blindness, mostly first recognized in childhood (5~10 years). Over subsequent years to decades, tunnel vision develops as the peripheral visual field gradually narrows. Central vision is preserved relatively long, but by mid-adulthood (40s~50s) severe visual impairment or blindness results. Once macular involvement begins, the rate of visual decline accelerates. Myopia commonly accompanies it, and posterior subcapsular cataract is also observed. The rate of progression of retinal lesions is associated with plasma ornithine concentration and pyridoxine responsiveness.
As an extraocular symptom, myopathy is reported in some patients. Muscle weakness and muscle cramps related to reduced creatine synthesis may occur, but severe degrees are rare. Intelligence is generally normal, and there are no serious neurological abnormalities. Hair abnormalities (twisted hair) are rarely reported.
Symptoms of HHH syndrome: the spectrum of presentation is broad. In the severe neonatal form, symptoms of acute hyperammonemia such as feeding refusal, lethargy, seizures and respiratory abnormalities appear shortly after birth, similar to OTC deficiency. In the late-onset form, episodes of hyperammonemia such as recurrent vomiting, headache and lethargy after high-protein meals occur intermittently from infancy to adulthood. Instinctive protein-avoidant eating habits are reported. Over the long-term course, spastic paraparesis appears progressively, the most characteristic neurological complication of HHH syndrome. Cognitive decline, developmental delay and learning disability are also reported.
Ophthalmological findings in gyrate atrophy: on funduscopy, characteristic circular or scalloped chorioretinal atrophic lesions begin in the equatorial region and extend toward the center and periphery. Initially, circular depigmented atrophic lesions are scattered, then gradually coalesce to form a wide zone of atrophy. Loss of the retinal pigment epithelium (RPE) and exposure of choroidal vessels are characteristic. The optic nerve is preserved relatively late. Fundus photography, fundus autofluorescence (FAF) and optical coherence tomography (OCT) are useful for assessing the extent and progression of lesions. On electroretinography (ERG), both rod and cone responses are reduced, in parallel with lesion progression.
Laboratory findings (common to both diseases): markedly elevated plasma ornithine (500~2,000 µmol/L, normal < 100 µmol/L) appears in both diseases. In gyrate atrophy, blood ammonia is normal or mildly elevated, and there is no homocitrullinuria. Ornithinuria may be seen on urine amino acids. HHH syndrome is characterized by hyperammonemia (marked during episodes, mild in stable periods), homocitrullinuria (pathognomonic) and reduced plasma citrulline. The presence or absence of homocitrullinuria is key to distinguishing the two diseases.
Neurological signs of HHH syndrome: lower limb spasticity, hyperreflexia and a positive Babinski sign are observed. Spinal MRI may show T2 signal abnormalities in the pyramidal tracts. EEG shows epileptiform discharges or generalized slow-wave abnormalities. Nerve conduction studies show findings of peripheral neuropathy in some patients.
Screening for ornithine metabolism disorders is based on blood amino acid analysis. Measuring blood ornithine (Orn) concentration by tandem mass spectrometry (MS/MS) in newborn screening can capture ornithine elevation in both diseases. However, because plasma ornithine has sometimes not yet risen greatly in the neonatal period, the possibility of false negatives must be considered. Because gyrate atrophy has no retinal symptoms in the neonatal period, confirmation by ophthalmological examination is needed even when it is detected on screening.
Family history-based screening: when a sibling is a confirmed patient, direct confirmation by molecular genetic testing is recommended. In high-risk families, early dietary intervention and ophthalmological follow-up can be started immediately, contributing to an improved prognosis.
In HHH syndrome, urine amino acid analysis (measurement of homocitrulline) plays an important role in screening and diagnosis. When elevated ornithine and reduced citrulline are confirmed on plasma amino acids and urinary homocitrulline is detected, HHH syndrome should be strongly suspected. This biochemical pattern is important for distinguishing it from OTC deficiency and CPSI deficiency.
Diagnosis of gyrate atrophy: ① markedly elevated plasma ornithine (> 400 µmol/L). ② Characteristic chorioretinal atrophy on funduscopy. ③ Abnormal electroretinogram (ERG). ④ Confirmation by molecular genetic testing (NGS analysis of the OAT gene). ⑤ Enzymatic confirmation is possible by measuring OAT enzyme activity in skin fibroblasts or lymphoblasts (< 5% of normal). To check pyridoxine responsiveness, a 2~6-week trial of high-dose vitamin B6 (300~500 mg/day) is given and any reduction in plasma ornithine is observed.
Diagnosis of HHH syndrome: ① elevated plasma ornithine. ② Elevated urinary homocitrulline (measured by high-performance liquid chromatography or amino acid analyzer; pathognomonic). ③ Elevated blood ammonia (during episodes). ④ Plasma amino acids: reduced citrulline, elevated glutamine. ⑤ Confirmation by molecular genetic testing (NGS analysis of the SLC25A15 gene). Because SLC25A15 is an inner mitochondrial membrane transporter, enzyme activity measurement is technically difficult, so molecular testing is preferred.
Treatment of gyrate atrophy: lowering plasma ornithine is the central treatment goal. ① Arginine-restricted diet: because arginine is a precursor of ornithine, intake of arginine-rich foods (meat, dairy products, nuts) is restricted. The goal is to keep plasma ornithine below 300 µmol/L with a low-arginine diet. With long-term dietary restriction, amino acid supplements (an essential amino acid mixture excluding arginine) are needed to prevent essential amino acid deficiency. ② Trial of pyridoxine (vitamin B6): because the OAT enzyme is PLP-dependent, an ornithine-lowering effect is expected in patients with pyridoxine-responsive variants, in whom high-dose pyridoxine (300~600 mg/day) increases residual enzyme activity. Some degree of responsiveness is reported in about 33% of patients. ③ Creatine supplementation: oral creatine supplementation is recommended to compensate for reduced creatine synthesis and support muscle function. Evidence for a retinal protective effect is limited, but it can be tried because it is not harmful. ④ Proline supplementation: tried on the theoretical basis of compensating for reduced P5C due to OAT deficiency and the resulting proline shortage. ⑤ Low-vision rehabilitation (assistive devices, magnifiers, Braille education, etc.) is applied step by step as visual decline progresses.
Treatment of HHH syndrome: urea cycle disorder management in line with OTC deficiency is applied. ① Low-protein diet (protein restriction, essential amino acid mixture supplementation). ② Oral citrulline supplementation (preserving residual urea cycle capacity). ③ Emergency management during acute hyperammonemic episodes (stopping protein, intravenous glucose and lipids, agents promoting ammonia excretion). ④ Drugs that cause hyperammonemia, such as valproic acid, are contraindicated. ⑤ Neurological rehabilitation for spastic paraplegia (physical therapy, consideration of antispasticity agents).
Prognosis of gyrate atrophy: without treatment, most patients reach legal blindness (best-corrected visual acuity < 0.1) in their 40s~60s. Long-term cohort studies show that keeping plasma ornithine low through dietary restriction (arginine restriction) clearly reduces the rate of progression of retinal atrophy. In pyridoxine-responsive patients, additional inhibition of progression is possible with pyridoxine. However, once retinal atrophy has occurred it cannot be reversed, so early diagnosis and early dietary intervention are most important. Intelligence and general health are generally preserved, and quality of life apart from vision is relatively good.
Prognosis of HHH syndrome: if hyperammonemic episodes are prevented with an appropriate low-protein diet and ammonia management, cognitive function and neurodevelopment can be largely preserved. However, spastic paraplegia is difficult to prevent completely with dietary control alone and shows a progressive course in some patients. In patients who experienced acute hyperammonemia in the neonatal period, early neurological damage determines the long-term cognitive prognosis. Liver transplantation can also prevent hyperammonemic episodes in HHH syndrome, but its effect on spastic paraplegia is uncertain.
Primary prevention: because both diseases are autosomal recessive, carrier testing and genetic counseling for patients' families (siblings, parents) are important. Carrier couples can choose prenatal diagnosis (CVS or amniocentesis) or preimplantation genetic testing (PGT) during pregnancy.
Secondary and tertiary prevention of gyrate atrophy: a low-arginine diet is started immediately upon diagnosis to keep plasma ornithine low. Progression of retinal lesions is monitored with ophthalmological examinations (fundus photography, OCT, ERG) 1~2 times a year. UV-blocking glasses are sometimes recommended on the theoretical concern that UV exposure may accelerate RPE damage, but the level of evidence is low. Low-vision aids and visual rehabilitation programs are provided alongside.
Secondary and tertiary prevention of HHH syndrome: the keys are avoiding drugs that cause hyperammonemia, such as valproic acid, refraining from high-protein meals, and early hospitalization and intensive management during metabolic stress such as infection or surgery. An emergency management plan is written and shared with medical staff, and patient and family education strengthens the ability to recognize episodes early.
Valle D, Kaiser-Kupfer MI, Del Valle LA. Gyrate atrophy of the choroid and retina: deficiency of ornithine aminotransferase in transformed lymphocytes. Proc Natl Acad Sci USA. 1977;74(11):5159-5161. DOI: 10.1073/pnas.74.11.5159. PMID: 269371.
Takki K. Gyrate atrophy of the choroid and retina associated with hyperornithinaemia. Br J Ophthalmol. 1974;58(1):3-23. DOI: 10.1136/bjo.58.1.3. PMID: 4128763.
Martinelli D, Diodato D, Ponzi E, et al. The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome. Orphanet J Rare Dis. 2015;10:29. DOI: 10.1186/s13023-015-0242-9. PMID: 25887472.
Brody LC, Mitchell GA, Obie C, et al. Ornithine delta-aminotransferase mutations in gyrate atrophy. J Biol Chem. 1992;267(5):3302-3307. PMID: 1737787.
Salvi S, Buonamici G, Falsini B, et al. Clinical, biochemical and molecular analysis in a cohort of individuals with gyrate atrophy. J Inherit Metab Dis. 2023;46(5):976-987. DOI: 10.1002/jimd.12642. PMID: 37539716.
Kaiser-Kupfer MI, Caruso RC, Valle D. Gyrate atrophy of the choroid and retina: further experience with long-term reduction of ornithine levels in late-onset disease. Arch Ophthalmol. 2002;120(2):146-153. DOI: 10.1001/archopht.120.2.146. PMID: 11831917.
Camacho JA, Obie C, Biery B, et al. Hyperornithinaemia-hyperammonaemia-homocitrullinuria syndrome is caused by mutations in a gene encoding a mitochondrial ornithine transporter. Nat Genet. 1999;22(2):151-158. DOI: 10.1038/9658. PMID: 10369254.
Häberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision. J Inherit Metab Dis. 2019;42(6):1192-1230. DOI: 10.1002/jimd.12100. PMID: 30982989.
Ramesh V, McClatchey AI, Ramesh N, et al. Molecular basis of ornithine aminotransferase deficiency in B-6-responsive and -nonresponsive forms of gyrate atrophy. Proc Natl Acad Sci USA. 1988;85(11):3777-3780. DOI: 10.1073/pnas.85.11.3777. PMID: 2836862.
Iyer R, Jenkinson CP, Vockley JG, et al. The human arginases and arginase deficiency. J Inherit Metab Dis. 1998;21 Suppl 1:86-100. DOI: 10.1023/a:1005323717143. PMID: 9686347.